ライフサイエンスコーパス: palliative treatment

1 l therapeutic alternatives are available for palliative treatment.

2 % were deceased, and 11.7% were on active or palliative treatment.

3 enerative disorder with no cure or effective palliative treatment.

4 causes), withdrawal of consent, or switch to palliative treatment.

5 watchful-waiting group have not required any palliative treatment.

6 wever, 4 Gy remains a useful alternative for palliative treatment.

7 e of emerging technologies for diagnosis and palliative treatment.

8 agnosed late-stage when their only option is palliative treatment.

9 3 to 0.44; P < .001) compared with receiving palliative treatment.

10 ividuals with HAM/TSP as a compassionate and palliative treatment.

11 given the option of curative treatments over palliative treatments.

12 medicine by providing curative, rather than palliative, treatments.

13 CIPANTS: The Assessing Doctors' Attitudes on Palliative Treatment (ADAPT) survey was distributed elec

14 udy used the Assessing Doctors' Attitudes on Palliative Treatment (ADAPT) survey, which was developed

15 onchoscopic lung volume reduction (bLVR) are palliative treatments aimed at reducing hyperinflation i

16 Chemotherapy treatment was mainly used for palliative treatment and was reported in three studies.

17 r, we reviewed the evidence on commonly used palliative treatments and their effect on quality of lif

18 cause of worldwide mortality for which only palliative treatments are available for patients with la

19 Although several palliative treatments are available, there is currently

20 ordance about prognosis, misconceptions that palliative treatments are curative, and disputes about p

21 Effective and tolerable palliative treatments are needed for patients with incur

22 ) is a chronic autoimmune disease, with only palliative treatments available.

23 unately, most patients are suitable only for palliative treatment because of the extent of their tumo

24 Both received palliative treatment consisting of fully covered self-ex

25 ere for imaging studies; 68 (15.5%) were for palliative treatments, excluding chemotherapy or radiati

26 represents a major unmet medical need; only palliative treatments exist for this group of debilitati

27 sticum is currently incurable, although some palliative treatments exist.

28 ucocorticoid treatment represents a standard palliative treatment for Duchenne muscular dystrophy (DM

29 The optimal palliative treatment for MBO is unclear due to the pauci

30 ume-reduction surgery has been proposed as a palliative treatment for severe emphysema.

31 better understand the benefits and burden of palliative treatments for patients with recurrent head a

32 ged 65 years and older deemed fit enough for palliative treatment had more toxicities or a worse outc

33 A variety of palliative treatments have evolved, but because of a low

34 en during sleep may be useful as a temporary palliative treatment in children with obstructive sleep

35 se agents have shown evidence of efficacy as palliative treatments in patients with metastatic or ino

36 stage III or IV solid tumor or lymphoma with palliative treatment intent, and impairment in 1 or more

37 tive disorders are incurable, and often only palliative treatment is available.

38 cure at presentation and those for whom only palliative treatment is possible.

39 There is no cure for ARVC5 and palliative treatment is started once the phenotype is pr

40 nting has been reported to be effective as a palliative treatment, it is not curative.

41 st frequent tumor site: genitourinary (45%); palliative treatment: n = 41 (34%)].

42 Palliative treatment of bone metastasis using radiolabel

43 fficacy outcomes for PRFE therapy use in the palliative treatment of both postoperative and nonpostop

44 we investigated CT-only GTV delineation for palliative treatment of head and neck cancer.

45 a total cost of epidemic, including cost of palliative treatment of ill individuals and preventive c

46 red SEMS is an effective and safe method for palliative treatment of MBO.

47 eful adjunct to standard chemotherapy in the palliative treatment of metastatic breast cancer.

48 s, within admissible limits of toxicity, for palliative treatment of metastatic NSCLC.

49 utic backbone for neoadjuvant, adjuvant, and palliative treatment of pancreatic ductal adenocarcinoma

50 ith high-risk stage II and stage III cancer, palliative treatment of patients with metastatic disease

51 rpose To evaluate the safety and efficacy of palliative treatment of patients with pathologic pelvic

52 e three times higher than those recommending palliative treatment only (40.41 vs 12.19; p < 0.01).

53 mmendations for further medical treatment or palliative treatment only at the end of life may influen

54 commend continuing full medical treatment or palliative treatment only.

55 fosine solution is confirmed as an effective palliative treatment option for cutaneous metastases fro

56 s with metastatic breast cancer because many palliative treatment options are available.

57 ng with emotion, (6) describing surgical and palliative treatment options, (7) eliciting patient's go

58 is commonly undertaken in both curative and palliative treatment plans.

59 zing patient preference is paramount in this palliative treatment setting.

60 h metastatic prostate carcinoma who received palliative treatment that did and did not include 89Sr-c

61 sfunction, and treatment is often limited to palliative treatment that provides only temporary relief

62 Unfortunately, other than palliative treatments there is no effective therapy for

63 Despite multiple available curative and palliative treatments, there is a lack of systematic eva

64 antly shorter progression-free survival upon palliative treatment with cetuximab plus chemotherapy or

65 thin a neighborhood of certain size and only palliative treatment with no prevention.